Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 9/20 | 0.37 |
| ▸ | PRKDC | P78527 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALB | P02768 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17449171 | 0.84 | ERN1 (0.33) | ERN1PRKDCCYP3A4MAPT | |
| SCHEMBL22060773 | 0.84 | CYP3A4 (0.36) | ERN1PRKDCCYP3A4MAPTALDH1A1 | |
| SCHEMBL22587805 | 0.84 | CYP3A4 (0.46) | ERN1CYP3A4MAPTUSP2ALB | |
| SCHEMBL31039195 | 0.84 | ERN1 (0.33) | ERN1PRKDCCYP3A4MAPT | |
| SCHEMBL23663290 | 0.84 | MEN1 (0.37) | ERN1PRKDCCYP3A4MAPTALDH1A1 | |
| SCHEMBL27042897 | 0.83 | LMNA (0.34) | ERN1CYP3A4MAPTALDH1A1LMNA | |
| SCHEMBL9279963 | 0.81 | ERN1 (0.51) | ERN1PRKDCCYP3A4MAPTALDH1A1 | |
| SCHEMBL20786945 | 0.78 | ERN1 (0.51) | ERN1PRKDCCYP3A4MAPTALDH1A1 | |
| SCHEMBL27042696 | 0.78 | KDM4E (0.34) | MAPT | |
| SCHEMBL1929437 | 0.78 | ERN1 (0.44) | ERN1CYP3A4MAPTALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102643213-B | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2014-04-09 | — | — | CN | claimed |
| CN-102643213-A | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-08-22 | — | — | CN | claimed |
| CN-122036699-A | THR-beta modulators and methods of use thereof | 阿利戈斯治疗公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-07 | — | — | US | disclosed |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | CELGENE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | CELGENE CORPORATION (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4662219-A2 | PRODRUGS OF THYROID HORMONE ANALOGS, METHODS OF MAKING AND METHODS OF USING THEREOF | ASCLETIS PHARMA (CHINA) CO., LIMITED (HK) | 2025-12-17 | — | — | EP | disclosed |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-30 | — | — | US | disclosed |
| EP-4633736-A1 | HETEROCYCLIC COMPOUNDS AS MODULATORS OF S1P5 | Celgene Corporation (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| WO-2008021851-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-6288101-B1 | ADMINISTERING COMPOUNDS SUCH AS 2,6-DIMETHYL-4-ISOPROPYLBENZALDEHYDE TO TREAT INDICATIONS WHERE STIMULATION OF SUBTYPES OF THE SEROTONIN RECEPTOR IS IMPLICATED, SUCH AS MIGRAINES | VIRGINIA COMMONWEALTH UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
| US-6124338-A | TREATING MIGRAINE HEADACHE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6048862-A | Benzylamidine derivatives with serotonin receptor binding activity | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2000-04-11 | — | — | US | disclosed |
| US-5969137-A | TREATMENT OF NERVOUS SYSTEM DISORDERS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1998012183-A1 | IMIDAZOLES WITH SEROTONIN RECEPTOR BINDING ACTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-03-26 | — | — | WO | disclosed |
| EP-0103957-B1 | SUBSTITUTED BENZYL ESTERS, INTERMEDIATES THEREFOR, PROCESSES FOR THEIR PREPARATION AND THE USE OF THE ESTERS AS PESTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-04-20 | — | — | EP | disclosed |
| US-4515808-A | INSECTICIDES | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1985-05-07 | — | — | US | disclosed |
| EP-0103957-A2 | Substituted benzyl esters, intermediates therefor, processes for their preparation and the use of the esters as pesticides | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | ERN1 1900/4885PRKDC 3652/4885CYP3A4 811/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | ERN1 1141/4885PRKDC 783/4885CYP3A4 3296/4885 |
| US-20260022094-A1 | Compounds for the Treatment of Neurodegenerative Diseases | S1PR5, CLN6, S1PR1 | ERN1 2388/4885PRKDC 4452/4885CYP3A4 4138/4885 |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | FSHR, CYP19A1, GPER1 | ERN1 1115/4885PRKDC 4160/4885CYP3A4 305/4885 |
| US-20250333424-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, IRF3 | ERN1 427/4885PRKDC 2300/4885CYP3A4 1549/4885 |
| US-12552771-B2 | Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases | S1PR5, CLN6, SNCA | ERN1 3086/4885PRKDC 4235/4885CYP3A4 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.